Joint Formulary & PAD

Bicalutamide - Prostate cancer

You are here : Home > Formulary Search > Bicalutamide - Prostate cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

To be prescribed on recommendation from a specialist.

Documentation

Evidence Review
Bicalutamide - Change in Traffic Light Status request - Oct 2016

PAD Profile

ChemicalSubstance :
Bicalutamide
Indication :
Prostate cancer
Group Name :
Keywords :
Brand Names Include :
Casodex
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

GENERIC Bicalutamide has been considered by the PCN and has been assigned a BLUE traffic light status. Note added January 2025 - this drug should be prescribed on recommendation from a specialist.

NOTE - the branded product, Casodex, was considered BLACK at the PCN in May 2017.

Other Indications

Below are listed other indications that Bicalutamide is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Prostate cancer.